A Phase 1 interventional study of Mirikizumab - IV and Mirikizumab - SC in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug. It will last up to about 4 months for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 300 milligram (mg), 600 mg and 1200 mg mirikizumab administered IV using a forearm vein infused over at least 30 minutes, 60 minutes and 2 hours.
Drug: Mirikizumab - IV
Participants received a single dose of placebo administered IV using a forearm vein.
Drug: Placebo - IV
Participants received a single dose of 200 mg, 400 mg mirikizumab administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).
Drug: Mirikizumab - SC
Participants received a single dose of placebo administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).
Drug: Placebo - SC
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Administered IV
Administered SC
Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs)
Drug-related TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. A summary of serious adverse events (SAEs) and other non-serious adverse events (NSAEs), regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.
Time frame: Baseline through Day 85
Visual Analog Scale (VAS) Pain Score for Subcutaneous Injection Site
The injection pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. The severity of pain was categorized by VAS pain score as: no pain (0), mild pain ≤ 30, moderate pain (\>30 and ≤70), and severe pain (\>70). Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).
Time frame: 0 min, 0.25 hours (h), 0.5 h, 1 h, 2 h and 4 h post first injection
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab
PK: Cmax of Mirikizumab was evaluated.
Time frame: Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab
PK: AUC(0-∞) of Mirikizumab was evaluated.
Time frame: Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose
PK: AUC From Time Zero to Time T, Where T is the Last Sample With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab
PK: AUC(0-tlast) of Mirikizumab was evaluated.
Time frame: Pre-dose, [end of infusion (EOI) IV only], Day 1: 6 hours (h), Day 2, Day 4, Day 8, Day 11 (SC only), Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, and Day 85 postdose
| Milestone | Placebo Intravenous (IV) | 300 Milligram (mg) Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo Subcutaneous (SC) | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|---|---|---|---|
| Started | 6 | 10 | 10 | 10 | 4 | 10 | 10 |
| Received at least one dose of study drug | 6 | 10 | 10 | 10 | 4 | 10 | 10 |
| Completed | 6 | 10 | 10 | 9 | 4 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Drug-related TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. A summary of serious adverse events (SAEs) and other non-serious adverse events (NSAEs), regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.
| participants | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs) | 1 | 3 | 4 | 1 | 1 | 0 | 0 |
The injection pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. The severity of pain was categorized by VAS pain score as: no pain (0), mild pain ≤ 30, moderate pain (\>30 and ≤70), and severe pain (\>70). Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).
| millimeter (mm) | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|
| 0 min | 36.5 ± 36.3 | 30.8 ± 29.5 | 42.4 ± 26.0 |
| 0.25 h | 3.5 ± 3.3 | 2.9 ± 3.7 | 10.6 ± 20.2 |
| 0.5 h | 2.3 ± 2.6 | 1.9 ± 3.4 | 9.5 ± 23.1 |
| 1 h | 1.0 ± 0.8 | 1.6 ± 1.9 | 2.0 ± 1.8 |
| 2 h | 1.8 ± 1.0 | 1.2 ± 1.5 | 2.0 ± 2.0 |
| 4 h | 1.0 ± 0.8 | 1.0 ± 1.2 | 2.1 ± 2.6 |
PK: Cmax of Mirikizumab was evaluated.
| microgram per milliliter (μg/mL) | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab | 145 ± 7 | 266 ± 16 | 511 ± 10 | 14.9 ± 28 | 23.1 ± 44 |
PK: AUC(0-∞) of Mirikizumab was evaluated.
| microgram*day per milliliter (μg*day/mL) | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab | 936 ± 12 | 2030 ± 12 | 3320 ± 23 | 263 ± 29 | 421 ± 46 |
PK: AUC(0-tlast) of Mirikizumab was evaluated.
| μg*day/mL | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|---|---|
| PK: AUC From Time Zero to Time T, Where T is the Last Sample With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab | 964 ± 15 | 2010 ± 12 | 3300 ± 24 | 248 ± 34 | 417 ± 46 |
Collected over Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo IV | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| 300 mg Mirikizumab IV | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| 600 mg Mirikizumab IV | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| 1200 mg Mirikizumab IV | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Placebo SC | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| 200 mg Mirikizumab SC | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| 400 mg Mirikizumab SC | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC |
|---|---|---|---|---|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 1/6 | 3/10 | 0/10 | 0/10 | 0/4 | 0/10 | 0/10 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/10 | 0/10 | 0/10 | 1/4 | 0/10 | 0/10 |
| BronchitisInfections and infestations | 0/6 | 0/10 | 0/10 | 0/10 | 1/4 | 0/10 | 0/10 |
| Animal scratchInjury, poisoning and procedural complications | 0/6 | 0/10 | 0/10 | 0/10 | 1/4 | 0/10 | 0/10 |
| Ligament sprainInjury, poisoning and procedural complications | 0/6 | 0/10 | 0/10 | 0/10 | 1/4 | 0/10 | 0/10 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 0/10 | 0/10 | 0/10 | 1/4 | 0/10 | 0/10 |
| Blood uric acid increasedInvestigations | 1/6 | 1/10 | 2/10 | 1/10 | 1/4 | 0/10 | 2/10 |
| Platelet count decreasedInvestigations | 0/6 | 0/10 | 0/10 | 0/10 | 1/4 | 0/10 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 2/10 | 0/10 | 0/10 | 0/4 | 1/10 | 1/10 |
| Blood potassium decreasedInvestigations | 0/6 | 0/10 | 0/10 | 0/10 | 0/4 | 0/10 | 2/10 |
All randomized participants.
| Age, Continuous(years) | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 26.0 ± 6.2 | 32.4 ± 6.4 | 31.7 ± 5.3 | 36.5 ± 6.1 | 25.0 ± 5.0 | 33.9 ± 7.2 | 31.8 ± 6.2 | 32.0 ± 6.8 |
| Sex: Female, Male(Participants) | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 4 | 4 | 4 | 0 | 5 | 4 | 23 |
| Male | 4 | 6 | 6 | 6 | 4 | 5 | 6 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 10 | 10 | 10 | 4 | 10 | 10 | 60 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 10 | 10 | 10 | 4 | 10 | 10 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo IV | 300 mg Mirikizumab IV | 600 mg Mirikizumab IV | 1200 mg Mirikizumab IV | Placebo SC | 200 mg Mirikizumab SC | 400 mg Mirikizumab SC | Total |
|---|---|---|---|---|---|---|---|---|
| China | 6 | 10 | 10 | 10 | 4 | 10 | 10 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Dec 2020, 12 months.
Results were first posted in Jan 2024, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab